Abstract
HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality. Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing risk for severe disease and death. While some HSCT recipients, particularly those who are early post-transplant and severely immunosuppressed, may have diminished response to COVID-19 vaccines, the benefits of vaccination are uncontested. Public health, healthcare facility and individual level approaches are all necessary to mitigate risk for infection in this vulnerable population.
Original language | English (US) |
---|---|
Article number | 101399 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 35 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2022 |
Keywords
- COVID-19
- HSCT
- Hematopoietic stem cell transplant
- Prevention
- SARS-CoV-2
- Treatment
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry